OBJECTIVE: To evaluate ABO blood group as a prognostic marker in patients with renal cell carcinoma (RCC).
PATIENTS AND METHODS: This retrospective study included 556 consecutive patients, who underwent surgery for RCC at a single institution. Associations of ABO blood group with clinical and pathological variables were assessed with Kruskal-Wallis tests and chi-square tests. The impact on overall and RCC-specific survival was analyzed with univariable and multivariable Cox proportional hazards regression models.
RESULTS: Blood group O was associated with absence of lymph node metastases (P=0.034) and presence of bilateral RCC (P=0.017). No associations with age, gender, body mass index, Charlson's co-morbidity index, T stage, M stage, grade and histological subtype were observed. In univariable and multivariable survival analysis, ABO blood group was not associated with overall and RCC-specific survival.
CONCLUSIONS: In this study, ABO blood group was not linked with RCC prognosis. Blood group O may be associated with absence of lymph node metastases and presence of bilateral RCC. External validation in larger cohorts is necessary.
Written by:
de Martino M, Waldert M, Haitel A, Schatzl G, Shariat SF, Klatte T. Are you the author?
Department of Urology, Medical University of Vienna, Vienna, Austria.
Reference: BJU Int. 2013 Sep 5. Epub ahead of print.
doi: 10.1111/bju.12436
PubMed Abstract
PMID: 24053513
UroToday.com Renal Cancer Section
